SHANGHAI, April 6, 2023 /PRNewswire/ — Mabwell (688062.SH), an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted site-specific ADC asset (R&D code: 9MW2821) demonstrated promising clinical data. The preliminary data show positive…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.